The growing interest in ivermectin as a possible treatment for patients infected with SARS-CoV-2, the virus behind the COVID-19 pandemic, was triggered by a laboratory experiment in a cell culture undertaken by Australian-based scientists at Monash University and the Peter Doherty Institute. In preclinical cell culture experiments, they found that the antiparasitic drug zaps the novel coronavirus. Despite some prominent critics, who imply that time shouldn’t be wasted on ivermectin in the context of a COVID-19 treatment, a wave of primarily pilot clinical trials has ensued, including randomized controlled trials at Johns Hopkins University and the University of Kentucky involving ivermectin. Now, the Leona M. and Harry B. Helmsley Charitable Trust (Helmsley Trust) in New York awarded Monash University a donation of $1.4 million to find the optimal dosage to ensure safety and efficacy; along with a commitment to fully fund a rapid-result dosing trial.
The Australian Catalyst Lab Study
TrialSite News was one of the first online media sites to not only report on this study but also initiate engagement with researchers worldwide. The original study was published in Ant...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).